Possible curative options for HCC such as tumour resection, liver transplant or ablation are at present limited to a minority of patients who are diagnosed at an early stage of the disease.4 For more advanced HCC, approved systemic therapies include multikinase inhibitors and agents targeting vascular endothelial growth factor (VEGF). This evidence concerns the gene VEGFA and hepatocellular carcinoma.